|
Efficacy and safety of IO103 a novel anti PD-L1 vaccine in basal cell carcinoma. |
| |
|
Research Funding - iOMEDICO |
Travel, Accommodations, Expenses - Janssen |
| |
|
Research Funding - iOMEDICO |
| |
|
Research Funding - iOMEDICO |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
| |
|
Stock and Other Ownership Interests - iOMEDICO |
Honoraria - GLS; Merck KGaA; MSD |
Consulting or Advisory Role - iOMEDICO |
Research Funding - iOMEDICO |
Patents, Royalties, Other Intellectual Property - Several |
Travel, Accommodations, Expenses - iOMEDICO; Merck; MSD |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |